As discussed, many types of inhibitors have been developed to abrogate activation and signaling of this pathway, and several of these HGF/c-Met targeting agents have been evaluated in completed or on-going clinical trials for HNSCC patients as summarized in Table 4. The gene discussed is HGF; the disease is head and neck squamous cell carcinoma.